Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (5183)	12/20/2001 2:51:46 PM
From: Ian@SI	Read Replies (1) \| Respond to of 52153

Peter, It seems even more sinister than that. On the surface, it may just be a ploy to keep the profits from an expanding market for the drugs out of CEPH's bottom line and put them into the joint venture. No incremental R&D, no FDA risk, just Marketing and Sales risks. If I were a CEPH shareholder, I'd certainly want to look at the prospectus with a view to ensuring that shareholder's assets aren't being unfairly disposed of. FWIW, Ian